Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Attitudes toward Medication and Reasons for Non-Compliance in Patients with Schizophrenia.

Chandra IS, Kumar KL, Reddy MP, Reddy CM.

Indian J Psychol Med. 2014 Jul;36(3):294-8. doi: 10.4103/0253-7176.135383.

2.

[Relationships between insight and medication adherence in subjects with psychosis].

Droulout T, Liraud F, Verdoux H.

Encephale. 2003 Sep-Oct;29(5):430-7. French.

PMID:
14615692
4.

[Cannabis and schizophrenia: demographic and clinical correlates].

Dervaux A, Laqueille X, Bourdel MC, Leborgne MH, Olié JP, Lôo H, Krebs MO.

Encephale. 2003 Jan-Feb;29(1):11-7. French.

PMID:
12640322
5.

[Factors related to suicide attempts in a Tunisian sample of patients with schizophrenia].

Bouhlel S, M'solly M, Benhawala S, Jones Y, El-Hechmi Z.

Encephale. 2013 Feb;39(1):6-12. doi: 10.1016/j.encep.2012.06.003. Epub 2012 Sep 25. French.

PMID:
23095582
6.

Compliance in schizophrenia: psychopathology, side effects, and patients' attitudes toward the illness and medication.

Rettenbacher MA, Hofer A, Eder U, Hummer M, Kemmler G, Weiss EM, Fleischhacker WW.

J Clin Psychiatry. 2004 Sep;65(9):1211-8.

PMID:
15367047
7.

Treatment compliance of outpatients with schizophrenia: patient's attitudes, demographic, clinical and therapeutic variables.

Stanković Z, Britvić D, Vuković O, Ille T.

Psychiatr Danub. 2008 Mar;20(1):42-52.

PMID:
18376330
8.

A study of reasons of non-compliance of psychiatric treatment and patients' attitudes towards illness and treatment in Qatar.

Bener A, Dafeeah EE, Salem MO.

Issues Ment Health Nurs. 2013 Apr;34(4):273-80. doi: 10.3109/01612840.2012.745039.

PMID:
23566190
9.

Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight.

Freudenreich O, Cather C, Evins AE, Henderson DC, Goff DC.

J Clin Psychiatry. 2004 Oct;65(10):1372-6.

PMID:
15491241
10.

Analysis of variables affecting drug compliance in schizophrenia.

Ansari S, Mulla S.

Ind Psychiatry J. 2014 Jan;23(1):58-60. doi: 10.4103/0972-6748.144968.

11.

The effectiveness of compliance therapy on drug attitude among schizophrenic patients: a systematic review.

Chang YT, Lee LL.

JBI Database System Rev Implement Rep. 2015 Aug 14;13(7):213-40. doi: 10.11124/jbisrir-2015-978. Review.

PMID:
26455856
12.
13.

How do socio-demographic and clinical factors interact with adherence attitude profiles in schizophrenia? A cluster-analytical approach.

Beck EM, Cavelti M, Wirtz M, Kossowsky J, Vauth R.

Psychiatry Res. 2011 May 15;187(1-2):55-61. doi: 10.1016/j.psychres.2010.10.012. Epub 2010 Nov 12.

PMID:
21074860
14.

Treatment adherence and insight in schizophrenia.

Bitter I, Fehér L, Tényi T, Czobor P.

Psychiatr Hung. 2015;30(1):18-26.

PMID:
25867885
15.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

16.

Association of symptom severity, insight and increased pharmacologic side effects in acutely hospitalized patients with schizophrenia.

Zhang J, Rosenheck R, Mohamed S, Zhou Y, Chang Q, Ning Y, He H.

Compr Psychiatry. 2014 Nov;55(8):1914-9. doi: 10.1016/j.comppsych.2014.07.018. Epub 2014 Jul 30.

PMID:
25217308
17.

Indicators of medication compliance in first-episode psychosis.

Kampman O, Laippala P, Väänänen J, Koivisto E, Kiviniemi P, Kilkku N, Lehtinen K.

Psychiatry Res. 2002 May 15;110(1):39-48.

PMID:
12007592
18.

[Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].

Misdrahi D, Delgado A, Bouju S, Comet D, Chiariny JF.

Encephale. 2013 May;39 Suppl 1:S8-14. doi: 10.1016/j.encep.2012.03.005. Epub 2013 Mar 28. French.

PMID:
23541914
19.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
20.

Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia.

Mohamed S, Rosenheck R, McEvoy J, Swartz M, Stroup S, Lieberman JA.

Schizophr Bull. 2009 Mar;35(2):336-46. doi: 10.1093/schbul/sbn067. Epub 2008 Jun 26.

Supplemental Content

Support Center